Skip to main content

Table 3 Comparisons of absorbance among groups treated with 30 μmol/L rosiglitazone for (6, 12, 24) h (mean ± SD)

From: Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro

groups

wells

Absorbance

control

 

3

0.23 ± 0.01

ANG II

6 h

3

0.52 ± 0.02*

ANG II + 30 μmol/L Ros

6 h

3

0.47 ± 0.02 ‡

 

12 h

3

0.44 ± 0.02 ‡ #

 

24 h

3

0.36 ± 0.03 ‡ ##

  1. *P < 0.01 versus control group; †P < 0.01 versus ANG II group; In rosiglitazone treatment groups, #P < 0.05 versus previous point in time, ##P < 0.01 versus previous point in time.